{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.201","value":"-0.65"},{"groupId":"OG001","spread":"2.062","value":"-0.68"}]}],"title":"Week 1, n=248, 492"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.983","value":"-0.88"},{"groupId":"OG001","spread":"2.809","value":"-1.06"}]}],"title":"Week 2, n=244, 495"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.374","value":"-1.30"},{"groupId":"OG001","spread":"2.488","value":"-1.30"}]}],"title":"Week 4, n=229, 488"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.464","value":"-1.42"},{"groupId":"OG001","spread":"2.652","value":"-1.68"}]}],"title":"Week 6, n=207, 476"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.793","value":"-1.89"},{"groupId":"OG001","spread":"2.810","value":"-2.11"}]}],"title":"Week 8, n=191, 473"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.985","value":"-2.18"},{"groupId":"OG001","spread":"3.440","value":"-2.83"}]}],"title":"Week 12, n=175, 453"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.247","value":"-2.37"},{"groupId":"OG001","spread":"3.798","value":"-3.32"}]}],"title":"Week 16, n=145, 406"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.684","value":"-3.08"},{"groupId":"OG001","spread":"4.040","value":"-3.99"}]}],"title":"Week 20, n=134, 378"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.148","value":"-4.04"},{"groupId":"OG001","spread":"4.175","value":"-4.75"}]}],"title":"Week 24, n=99, 265"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.749","value":"-4.57"},{"groupId":"OG001","spread":"5.016","value":"-5.09"}]}],"title":"Week 28, n=74, 212"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.397","value":"-4.50"},{"groupId":"OG001","spread":"5.369","value":"-5.52"}]}],"title":"Week 32, n=67, 200"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.739","value":"-4.54"},{"groupId":"OG001","spread":"7.476","value":"-5.39"}]}],"title":"Week 36, n=63, 188"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.612","value":"-4.99"},{"groupId":"OG001","spread":"5.571","value":"-5.87"}]}],"title":"Week 40, n=59, 174"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.475","value":"-4.79"},{"groupId":"OG001","spread":"5.661","value":"-5.89"}]}],"title":"Week 44, n=59, 168"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.361","value":"-3.28"},{"groupId":"OG001","spread":"5.180","value":"-4.69"}]}],"title":"End of Treatment, n=240, 470"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.318","value":"-2.78"},{"groupId":"OG001","spread":"6.381","value":"-3.84"}]}],"title":"4-week FU, n=223, 425"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.088","value":"-1.98"},{"groupId":"OG001","spread":"5.999","value":"-2.99"}]}],"title":"12-week FU, n=210, 434"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.568","value":"-1.36"},{"groupId":"OG001","spread":"7.683","value":"-1.51"}]}],"title":"24-week FU, n=205, 401"}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"description":"The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)","title":"Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"Kilograms (kg)"}